A study in The Lancet Oncology was supportive of proton radiotherapy, saying it is safe, or perhaps safer than conventional chemotherapy in the fight against cancer, at least among children with the most common malignant brain cancer (medulloblastomas). All 59 children received both forms of treatment. "Our findings suggest that proton radiotherapy seems to result in an acceptable degree of toxicity and had similar survival outcomes to those achieved with photon-based radiotherapy. Although there remain some effects of treatment on hearing, endocrine, and neurocognitive outcomes--particularly in younger patients--other late effects common in photon-treated patients, such as cardiac, pulmonary, and gastrointestinal toxic effects, were absent," the authors wrote. The arena earned med tech's largest financing last year (and one of the biggest overall), when Chinese investors HOPU Investments and YuanMing Capital led a $200 million round in anticancer proton therapy systems maker Mevion Medical. More
@FierceMedDev: ICYMI: Philips taps transportation exec in its effort to industrialize, personalize healthcare. Article | Follow @FierceMedDev
@VarunSaxena2: Which pharma character is #1? FiercePharmaMarketing report | Follow @VarunSaxena2
@EmilyWFierce: Abbott inks $5.8B deal for Alere to expand in point-of-care diagnostics. Report | Follow @EmilyWFierce
> Micro-cap non-invasive continuous glucose monitor company Echo Therapeutics ($ECTE) has made an agreement with investors to raise up to $5.1 million. More
> An opinion piece in The Herald calls for the U.K.'s National Health Service (NHS) to roll out pulse oximetry monitoring for all newborns. More
> Private wound care and regenerative medicine player Acelity plans to raise $400 million in debt. Last year, the company filed to raise up to $1 billion in an IPO. More
Biotech News
@FierceBiotech: ICYMI Friday: Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen. Article | Follow @FierceBiotech
@JohnCFierce: Will Zika frenzy fuel an overnight vaccine R&D miracle? Don't bet on it. More | Follow @JohnCFierce
@DamianFierce: this man missed a huge opportunity in orthopedics. More from STAT | Follow @DamianFierce
> The synNotch solution: UCSF scientists engineer a next-gen T-cell immunotherapy. Item
> Bristol-Myers, Pfizer and Eisai bet big biobucks on the Japanese market. Story
> Lilly considers taking the plunge on a next-gen GLP-1 drug for diabetes. More
Pharma News
@FiercePharma: Lilly closes two animal health factories, citing no 'competitive business model.' FierceAnimalHealth story | Follow @FiercePharma
@EricPFierce: ICYMI from FiercePharmaManufacturing: Novartis is revamping its manufacturing after having disposed of 25 plants. Article | Follow @EricPFierce
@CarlyHFierce: ICYMI: Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie. Article | Follow @CarlyHFierce
> Novartis braces for multibillion-dollar generics hit as Gleevec copies launch. Article
> Was Allergan's CEO simply touting a Texas plant expansion--or nudging watchdogs on Pfizer merger, too? More
> Roche sees no 'short term' pricing pressure for company's cancer drugs: Reuters. Story
Animal Health News
> Lilly closes two animal health factories, citing no 'competitive business model.' More
> IDEXX and Abaxis trade fortunes on Wall Street as earnings surprise investors. Story
> Merial teams with Georgia Tech to advance connected networks for animal health. Article
> Dog flu sweeps the U.S. with two more confirmed cases in Washington state. Report
> Aratana shares soar on first FDA filing for approval of canine arthritis drug. News
Biotech IT News
> CosmosID raises $6M to advance microbiome bioinformatics offering. Story
> BioClinica rolls out tech-enabled postapproval research service. Item
> DNAnexus connects genomics platform to Sapio Sciences' LIMS. More
> AstraZeneca taps CRISPR to extract value from genome data. Report
> Leo Pharma mounts $70M push into digital health technology. Article
Pharma Marketing News
> More link think? OPDP lists social media links as guidance item for 2016. Report
> Don't expect a generics-style smackdown from Remicade biosims, J&J CEO says. Story
> Novo's Tresiba scores data for a new edge in insulin fight against Sanofi. Article
> Roche's pharma chief sees no 'short term' pricing pressure on its cancer blockbusters. More
> Novartis retrains Entresto reps, plans field force expansion as payers finally step up. Report